NHS England Expands Access to Weight-Loss Drug for Heart Protection
NHS England is set to offer weight-loss drugs to more than 1.2 million people to reduce their risk of heart attacks and strokes. This expansion follows a green light from the National Institute for Health and Care Excellence (Nice), which has approved semaglutide, commonly known as Wegovy or Ozempic, for a broader group of patients.
Eligibility Criteria and New Guidelines
Under the new draft guidance, individuals who are not obese but overweight, with a body mass index (BMI) of 27 or above, and who have previously experienced a heart attack, stroke, or serious circulation issues in their legs, will be eligible for weekly semaglutide injections. This move aims to provide an extra layer of protection against life-threatening cardiovascular events.
Helen Knight, the director of medicines evaluation at Nice, emphasized the compelling evidence from clinical trials. "We know that people who have already had a heart attack or stroke are living with real fear that it could happen again. Today’s decision gives thousands of people in that situation an extra layer of protection, on top of the medicines they are already taking," she stated.
Clinical Evidence and Benefits Beyond Weight Loss
Clinical trials have demonstrated that semaglutide significantly reduces the risk of heart attack, stroke, or cardiovascular death. Crucially, this benefit occurs even before significant weight loss, suggesting the drug works directly on the heart and blood vessels, not just through weight reduction.
A landmark study led by University College London (UCL), published in the Lancet, found that semaglutide cuts the risk of heart attack or stroke regardless of weight loss. Previous analysis indicated a 20% reduction in major cardiac events, with recent research confirming this benefit is independent of weight changes.
Prof Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow, commented: "This is very good news and stems directly from high-quality trial evidence. We now have medicines that not only reduce heart attacks, strokes and peripheral arterial disease but also simultaneously lead to meaningful weight loss."
Implementation and NHS Capacity
NHS England officials have indicated that the new group of eligible patients will be able to access semaglutide within months. The weekly injections will be offered as an additional treatment alongside existing medications like statins, combined with a reduced-calorie diet and increased physical activity for those at high risk.
However, concerns have been raised about the NHS's capacity to deliver the drug to such a large population. Riyaz Patel, professor of cardiology at UCL, welcomed the move but noted: "There are questions over whether the NHS has the capacity to offer the drug to so many people. Overall, a really exciting development, for patients and doctors, giving us another powerful tool to reduce CVD risk."
Expert Endorsements and Future Impact
Health experts have praised the decision, highlighting the broader benefits of semaglutide. Dr Sonya Babu-Narayan, clinical director of the British Heart Foundation, stated that weight-loss drugs are now considered important medicines for preventing cardiovascular events, with proven benefits beyond weight reduction.
Helen Williams, NHS England’s clinical director for cardiovascular disease prevention, added: "For more than a million people at high risk of heart attack and stroke, this treatment on the NHS could be life-changing – offering a powerful new way to protect their hearts and improve their health."
Health Minister Sharon Hodgson described weight-loss drugs as a gamechanger and a potential lifesaver for those at risk of heart attacks and strokes.
This expansion marks a significant step in public health strategy, leveraging pharmaceutical advances to combat cardiovascular disease on a large scale within the NHS framework.
